Litt ’, D. Drug Eruptions and Reactions Manual. :462–4.

Gaist D, Andersen M, Schou J. Spontaneous Reports of Drug-Induced Erythema Multiforme, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Denmark 1968-1991. Pharmacoepidemiology and drug safety. 1996;79–86.

Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet Journal of Rare Diseases. 2010;5(1).

Mittmann N, Knowlessr K, Shear N, Rachils A, Rourke S. Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study. Am J Clin Dermatol. 2012;(1):49–54.

Tan S, Tay Y. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes. Acta Derm Venereol. 2012;(1):62–6.

Chung W, Hung S. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis. J Dermatol Sci. 2012;(3):190–6.

Chung W, Hung S. Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis. Allergol Int. 2010;(4):325–32.

Chung W, Hung S, Chen Y. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol. 2007;(4):317–23.

Hsiao Y, Hui R, Wu T, Chang W, Hsih M, Yang C, et al. Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations. J Dermatol Sci. 2014;(2):101–9.

Syed D, Iqbal O, Mosier M, Mitchell R, Hoppensteadt D, Bouchard C, et al. Elevated endocan levels and its association with clinical severity in stevens johnson syndrome and toxic epidermal necrolysis. Int Angiol. 2014;

Valeyrie-Allanore L, Bastuji-Garin S, Guégan S, Ortonne N, Bagot M, Roujeau J, et al. Prognostic value of histologic features of toxic epidermal necrolysis. J Am Acad Dermatol. 2013;(2):29–35.

Ellender R, Peters C, Albritton H, Garcia A, Kaye A. Clinical considerations for epidermal necrolysis. Ochsner J. 2014;(3):413–7.

Pozzo-Magana D, Lazo-Langner B, Carleton A, Castro-Pastrana B, Rieder L, M. A systematic review of treatment of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Popul Ther Clin Pharmacol. 2011;121–33.

Roongpisuthipong W, Prompongsa S, Klangjareonchai T. Retrospective Analysis of Corticosteroid Treatment in Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis over a Period of 10 Years in Vajira Hospital. Dermatol Res Pract. 2014;237821.

Yang Y, Xu J, Li F, Zhu X. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China. Int J Dermatol. 2009;(10):1122–8.

Gubinelli E, Canzona F, Tonanzi T, Raskovic D, Didona B. Toxic epidermal necrolysis successfully treated with etanercept. J Dermatol. 2009;(3):150–3.

English SJ.

Vojvodić A, Dinić M, Kostić K, Miltary M, Academy. Clinic for Dermatovenerology SUMMARY Stevens-Johnson syndrome (SJS) is a severe, episodic, acute mucocutaneous reaction that is most often elicited by drugs and occasionally by infections. The drugs commonly implicated as the cause of SJS are anticonvulsants, sulfonamides, non-steroidal anti-inflammatory drugs and antibiotics. Carbamazepine has been commonly implicated in SJS. We report a case of SJS-TEN overlap syndrome developing in patient who was prescribed carbamazeine after epileptic attack during radiotherapy for the purpose of treatment Glioblastoma multiforme, patients underlying disease.